Pfizer's Obesity Drug Breakthrough: A Weighty Market Move
Pfizer's experimental obesity drug, acquired through Metsera, shows promise, reporting up to 12.3% weight loss in a 28-week trial. Targeting regulatory approval by 2028, Pfizer plans over 20 clinical trials, eyeing the potential $150 billion market. Despite patent expirations, the company aims to boost growth with innovative treatments.
Pfizer announced on Tuesday that an experimental obesity drug, obtained via its $10 billion acquisition of Metsera, has demonstrated substantial weight loss after 28 weeks of treatment as a monthly injection.
The pharmaceutical giant is planning to seek regulatory approval by 2028 for what could be a lucrative addition to the rapidly expanding weight-loss medication market.
This move is seen as part of Pfizer's strategy to counter challenges, including patent expirations, by investing in blockbuster drugs.
Advertisement
ALSO READ
-
Pfizer's Bold Step in the Obesity Drug Market
-
Pfizer's High-Profile Obesity Drug: A Game Changer or Risky Bet?
-
Jammu & Kashmir Steps Up War on Drugs with Record Arrests and Convictions
-
Pfizer's $10 Billion Bet: The Future of Obesity Drugs
-
Novo Nordisk Fights to Reclaim Obesity Drug Market Amid Declining Sales
Google News